Study on COgnition and Prognosis in the Elderly (SCOPE): Baseline characteristics

Lennart Hansson, H. Lithell, I. Skoog, F. Baro, C. M. Bánki, M. Breteler, A. Castaigne, M. Correia, J. P. Degaute, D. Elmfeldt, K. Engedal, C. Farsang, J. Ferro, V. Hachinski, A. Hofman, O. F W James, E. Krisin, M. Leeman, P. W. De Leeuw, D. LeysA. Lobo, G. Nordby, B. Olofsson, G. Opolski, M. Prince, F. M. Reischies, J. B. Rosenfeld, L. Ruilope, J. Salerno, R. Tilvis, P. Trenkwalder, A. Zanchetti

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

The Study on COgnition and Prognosis in the Elderly (SCOPE) is a multi- centre, prospective, randomized, double-blind, parallel-group study. The primary objective of SCOPE is to assess the effect of the angiotensin II type 1 (AT1) receptor blocker, candesartan cilexetil 8-16 mg once daily, on major cardiovascular events in elderly patients (70-89 years of age) with mild hypertension (DBP 90-99 and/or SBP 160-179 mmHg). The secondary objectives of the study are to test the hypothesis that antihypertensive therapy can prevent cognitive decline (as measured by the Mini Mental State Examination, MMSE) and dementia, and to assess the effect of therapy on total mortality, myocardial infarction (MI), stroke, renal function, and hospitalization. A total of 4964 patients from 15 participating countries were recruited during the randomization phase of SCOPE, exceeding the target population of 4000. The mean age of the patients at enrolment was 76 years, the ratio of male to female patients was approximately 1:2, and 52% of patients were already being treated with an antihypertensive agent at enrolment. The majority of patients (88%) were educated to at least primary school level. At randomization, mean sitting blood pressure values were SBP 166 mmHg and DBP 90 mmHg, and the mean MMSE score was 28. Previous cardiovascular disease in the study population included myocardial infarction (4%), stroke (4%) and atrial fibrillation (4%). Men, more often than women, had a history of previous MI, stroke and atrial fibrillation. A greater percentage of men were smokers (13% vs 6% in women) and had attended university (11% vs 3% of women). Of the randomized patients, 21% were 80 years of age. In this age group smoking was less common (4% vs 10% for 70-79-year-olds) and fewer had attended university (4% vs 7% for 70-79-year-olds). The incidence of MI was similar in both age groups. However, stroke and atrial fibrillation had occurred approximately twice as frequently in the older patients. The patients' mean age at baseline was similar in the participating countries, and most countries showed the approximate 1:2 ratio for male to female patients. There was also little inter-country variation in terms of mean SBP, DBP or MMSE score. However, there was considerable regional variation in the percentage of patients on therapy prior to enrolment.

Original languageEnglish
Pages (from-to)146-151
Number of pages6
JournalBlood Pressure
Volume9
Issue number2-3
Publication statusPublished - 2000

Fingerprint

Cognition
Stroke
Myocardial Infarction
Atrial Fibrillation
Random Allocation
Antihypertensive Agents
Age Groups
Angiotensin II Type 1 Receptor Blockers
Health Services Needs and Demand
Dementia
Hospitalization
Cardiovascular Diseases
Therapeutics
Smoking
Blood Pressure
Hypertension
Kidney
Mortality
Incidence

Keywords

  • Candesartan cilexetil
  • Cognitive function
  • Elderly
  • Mild hypertension

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Hansson, L., Lithell, H., Skoog, I., Baro, F., Bánki, C. M., Breteler, M., ... Zanchetti, A. (2000). Study on COgnition and Prognosis in the Elderly (SCOPE): Baseline characteristics. Blood Pressure, 9(2-3), 146-151.

Study on COgnition and Prognosis in the Elderly (SCOPE) : Baseline characteristics. / Hansson, Lennart; Lithell, H.; Skoog, I.; Baro, F.; Bánki, C. M.; Breteler, M.; Castaigne, A.; Correia, M.; Degaute, J. P.; Elmfeldt, D.; Engedal, K.; Farsang, C.; Ferro, J.; Hachinski, V.; Hofman, A.; James, O. F W; Krisin, E.; Leeman, M.; De Leeuw, P. W.; Leys, D.; Lobo, A.; Nordby, G.; Olofsson, B.; Opolski, G.; Prince, M.; Reischies, F. M.; Rosenfeld, J. B.; Ruilope, L.; Salerno, J.; Tilvis, R.; Trenkwalder, P.; Zanchetti, A.

In: Blood Pressure, Vol. 9, No. 2-3, 2000, p. 146-151.

Research output: Contribution to journalArticle

Hansson, L, Lithell, H, Skoog, I, Baro, F, Bánki, CM, Breteler, M, Castaigne, A, Correia, M, Degaute, JP, Elmfeldt, D, Engedal, K, Farsang, C, Ferro, J, Hachinski, V, Hofman, A, James, OFW, Krisin, E, Leeman, M, De Leeuw, PW, Leys, D, Lobo, A, Nordby, G, Olofsson, B, Opolski, G, Prince, M, Reischies, FM, Rosenfeld, JB, Ruilope, L, Salerno, J, Tilvis, R, Trenkwalder, P & Zanchetti, A 2000, 'Study on COgnition and Prognosis in the Elderly (SCOPE): Baseline characteristics', Blood Pressure, vol. 9, no. 2-3, pp. 146-151.
Hansson L, Lithell H, Skoog I, Baro F, Bánki CM, Breteler M et al. Study on COgnition and Prognosis in the Elderly (SCOPE): Baseline characteristics. Blood Pressure. 2000;9(2-3):146-151.
Hansson, Lennart ; Lithell, H. ; Skoog, I. ; Baro, F. ; Bánki, C. M. ; Breteler, M. ; Castaigne, A. ; Correia, M. ; Degaute, J. P. ; Elmfeldt, D. ; Engedal, K. ; Farsang, C. ; Ferro, J. ; Hachinski, V. ; Hofman, A. ; James, O. F W ; Krisin, E. ; Leeman, M. ; De Leeuw, P. W. ; Leys, D. ; Lobo, A. ; Nordby, G. ; Olofsson, B. ; Opolski, G. ; Prince, M. ; Reischies, F. M. ; Rosenfeld, J. B. ; Ruilope, L. ; Salerno, J. ; Tilvis, R. ; Trenkwalder, P. ; Zanchetti, A. / Study on COgnition and Prognosis in the Elderly (SCOPE) : Baseline characteristics. In: Blood Pressure. 2000 ; Vol. 9, No. 2-3. pp. 146-151.
@article{2e53d64dda08419f92c073fe66520a95,
title = "Study on COgnition and Prognosis in the Elderly (SCOPE): Baseline characteristics",
abstract = "The Study on COgnition and Prognosis in the Elderly (SCOPE) is a multi- centre, prospective, randomized, double-blind, parallel-group study. The primary objective of SCOPE is to assess the effect of the angiotensin II type 1 (AT1) receptor blocker, candesartan cilexetil 8-16 mg once daily, on major cardiovascular events in elderly patients (70-89 years of age) with mild hypertension (DBP 90-99 and/or SBP 160-179 mmHg). The secondary objectives of the study are to test the hypothesis that antihypertensive therapy can prevent cognitive decline (as measured by the Mini Mental State Examination, MMSE) and dementia, and to assess the effect of therapy on total mortality, myocardial infarction (MI), stroke, renal function, and hospitalization. A total of 4964 patients from 15 participating countries were recruited during the randomization phase of SCOPE, exceeding the target population of 4000. The mean age of the patients at enrolment was 76 years, the ratio of male to female patients was approximately 1:2, and 52{\%} of patients were already being treated with an antihypertensive agent at enrolment. The majority of patients (88{\%}) were educated to at least primary school level. At randomization, mean sitting blood pressure values were SBP 166 mmHg and DBP 90 mmHg, and the mean MMSE score was 28. Previous cardiovascular disease in the study population included myocardial infarction (4{\%}), stroke (4{\%}) and atrial fibrillation (4{\%}). Men, more often than women, had a history of previous MI, stroke and atrial fibrillation. A greater percentage of men were smokers (13{\%} vs 6{\%} in women) and had attended university (11{\%} vs 3{\%} of women). Of the randomized patients, 21{\%} were 80 years of age. In this age group smoking was less common (4{\%} vs 10{\%} for 70-79-year-olds) and fewer had attended university (4{\%} vs 7{\%} for 70-79-year-olds). The incidence of MI was similar in both age groups. However, stroke and atrial fibrillation had occurred approximately twice as frequently in the older patients. The patients' mean age at baseline was similar in the participating countries, and most countries showed the approximate 1:2 ratio for male to female patients. There was also little inter-country variation in terms of mean SBP, DBP or MMSE score. However, there was considerable regional variation in the percentage of patients on therapy prior to enrolment.",
keywords = "Candesartan cilexetil, Cognitive function, Elderly, Mild hypertension",
author = "Lennart Hansson and H. Lithell and I. Skoog and F. Baro and B{\'a}nki, {C. M.} and M. Breteler and A. Castaigne and M. Correia and Degaute, {J. P.} and D. Elmfeldt and K. Engedal and C. Farsang and J. Ferro and V. Hachinski and A. Hofman and James, {O. F W} and E. Krisin and M. Leeman and {De Leeuw}, {P. W.} and D. Leys and A. Lobo and G. Nordby and B. Olofsson and G. Opolski and M. Prince and Reischies, {F. M.} and Rosenfeld, {J. B.} and L. Ruilope and J. Salerno and R. Tilvis and P. Trenkwalder and A. Zanchetti",
year = "2000",
language = "English",
volume = "9",
pages = "146--151",
journal = "Blood Pressure",
issn = "0803-7051",
publisher = "Informa Healthcare",
number = "2-3",

}

TY - JOUR

T1 - Study on COgnition and Prognosis in the Elderly (SCOPE)

T2 - Baseline characteristics

AU - Hansson, Lennart

AU - Lithell, H.

AU - Skoog, I.

AU - Baro, F.

AU - Bánki, C. M.

AU - Breteler, M.

AU - Castaigne, A.

AU - Correia, M.

AU - Degaute, J. P.

AU - Elmfeldt, D.

AU - Engedal, K.

AU - Farsang, C.

AU - Ferro, J.

AU - Hachinski, V.

AU - Hofman, A.

AU - James, O. F W

AU - Krisin, E.

AU - Leeman, M.

AU - De Leeuw, P. W.

AU - Leys, D.

AU - Lobo, A.

AU - Nordby, G.

AU - Olofsson, B.

AU - Opolski, G.

AU - Prince, M.

AU - Reischies, F. M.

AU - Rosenfeld, J. B.

AU - Ruilope, L.

AU - Salerno, J.

AU - Tilvis, R.

AU - Trenkwalder, P.

AU - Zanchetti, A.

PY - 2000

Y1 - 2000

N2 - The Study on COgnition and Prognosis in the Elderly (SCOPE) is a multi- centre, prospective, randomized, double-blind, parallel-group study. The primary objective of SCOPE is to assess the effect of the angiotensin II type 1 (AT1) receptor blocker, candesartan cilexetil 8-16 mg once daily, on major cardiovascular events in elderly patients (70-89 years of age) with mild hypertension (DBP 90-99 and/or SBP 160-179 mmHg). The secondary objectives of the study are to test the hypothesis that antihypertensive therapy can prevent cognitive decline (as measured by the Mini Mental State Examination, MMSE) and dementia, and to assess the effect of therapy on total mortality, myocardial infarction (MI), stroke, renal function, and hospitalization. A total of 4964 patients from 15 participating countries were recruited during the randomization phase of SCOPE, exceeding the target population of 4000. The mean age of the patients at enrolment was 76 years, the ratio of male to female patients was approximately 1:2, and 52% of patients were already being treated with an antihypertensive agent at enrolment. The majority of patients (88%) were educated to at least primary school level. At randomization, mean sitting blood pressure values were SBP 166 mmHg and DBP 90 mmHg, and the mean MMSE score was 28. Previous cardiovascular disease in the study population included myocardial infarction (4%), stroke (4%) and atrial fibrillation (4%). Men, more often than women, had a history of previous MI, stroke and atrial fibrillation. A greater percentage of men were smokers (13% vs 6% in women) and had attended university (11% vs 3% of women). Of the randomized patients, 21% were 80 years of age. In this age group smoking was less common (4% vs 10% for 70-79-year-olds) and fewer had attended university (4% vs 7% for 70-79-year-olds). The incidence of MI was similar in both age groups. However, stroke and atrial fibrillation had occurred approximately twice as frequently in the older patients. The patients' mean age at baseline was similar in the participating countries, and most countries showed the approximate 1:2 ratio for male to female patients. There was also little inter-country variation in terms of mean SBP, DBP or MMSE score. However, there was considerable regional variation in the percentage of patients on therapy prior to enrolment.

AB - The Study on COgnition and Prognosis in the Elderly (SCOPE) is a multi- centre, prospective, randomized, double-blind, parallel-group study. The primary objective of SCOPE is to assess the effect of the angiotensin II type 1 (AT1) receptor blocker, candesartan cilexetil 8-16 mg once daily, on major cardiovascular events in elderly patients (70-89 years of age) with mild hypertension (DBP 90-99 and/or SBP 160-179 mmHg). The secondary objectives of the study are to test the hypothesis that antihypertensive therapy can prevent cognitive decline (as measured by the Mini Mental State Examination, MMSE) and dementia, and to assess the effect of therapy on total mortality, myocardial infarction (MI), stroke, renal function, and hospitalization. A total of 4964 patients from 15 participating countries were recruited during the randomization phase of SCOPE, exceeding the target population of 4000. The mean age of the patients at enrolment was 76 years, the ratio of male to female patients was approximately 1:2, and 52% of patients were already being treated with an antihypertensive agent at enrolment. The majority of patients (88%) were educated to at least primary school level. At randomization, mean sitting blood pressure values were SBP 166 mmHg and DBP 90 mmHg, and the mean MMSE score was 28. Previous cardiovascular disease in the study population included myocardial infarction (4%), stroke (4%) and atrial fibrillation (4%). Men, more often than women, had a history of previous MI, stroke and atrial fibrillation. A greater percentage of men were smokers (13% vs 6% in women) and had attended university (11% vs 3% of women). Of the randomized patients, 21% were 80 years of age. In this age group smoking was less common (4% vs 10% for 70-79-year-olds) and fewer had attended university (4% vs 7% for 70-79-year-olds). The incidence of MI was similar in both age groups. However, stroke and atrial fibrillation had occurred approximately twice as frequently in the older patients. The patients' mean age at baseline was similar in the participating countries, and most countries showed the approximate 1:2 ratio for male to female patients. There was also little inter-country variation in terms of mean SBP, DBP or MMSE score. However, there was considerable regional variation in the percentage of patients on therapy prior to enrolment.

KW - Candesartan cilexetil

KW - Cognitive function

KW - Elderly

KW - Mild hypertension

UR - http://www.scopus.com/inward/record.url?scp=0034119826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034119826&partnerID=8YFLogxK

M3 - Article

C2 - 10855739

AN - SCOPUS:0034119826

VL - 9

SP - 146

EP - 151

JO - Blood Pressure

JF - Blood Pressure

SN - 0803-7051

IS - 2-3

ER -